Shares of Achieve Life Sciences Inc. (ACHV) were ticking slightly higher in premarket trading Thursday. That's a small bit of good news for a stock that's down about 43% so far this year. The company is navigating a tricky path: it's got a promising drug to help people quit smoking, but it's also dealing with regulatory speed bumps and pushing its commercial launch further into the future.

Building a U.S. Supply Chain

On Tuesday, Achieve announced a key manufacturing partnership. It's teaming up with Adare Pharma Solutions, a U.S.-based company, to produce its drug candidate, cytisinicline. The idea here is pretty straightforward. By making the drug domestically instead of importing it, Achieve hopes to cut down on risks like international shipping delays and potentially lower costs, including tariffs. It's a move that makes a lot of sense when you're gearing up to sell a product.

The company has already started the "technology transfer" process to get Adare up to speed. This partnership news came alongside the company's financial results for the fourth quarter and full year 2025. The numbers show the burn rate of a clinical-stage biotech: a net loss of $14.7 million for the quarter and a much larger $54.7 million loss for the full year. As of the end of December, Achieve had $36.4 million in cash and marketable securities left in the tank to fund its operations.

The 2027 Launch Plan and FDA Hurdles

So, when will this drug actually hit the market? Achieve now says it's targeting the first half of 2027 for a U.S. commercial launch. That's a shift from its previous expectation of 2026. Why the delay? The company disclosed that the U.S. Food and Drug Administration recently inspected one of the manufacturers named in its drug application. The FDA came away with two observations related to solid oral dose manufacturing. In regulator-speak, "observations" are issues that need to be fixed; they're not necessarily catastrophic, but they must be addressed.

Achieve says it's working on resolving those observations. Despite the delay, the company's CEO, Rick Stewart, sounded optimistic about the new manufacturing deal. "Establishing U.S. manufacturing with Adare increases our confidence in our supply chain and continues our strong progress towards launch," Stewart said.

Why All the Fuss About This Drug?

Cytisinicline isn't just another pill. The company and some outside observers believe it could be a significant advancement. In March, Achieve presented new data showing that 6 and 12 weeks of treatment with cytisinicline helped people quit smoking successfully. The data suggested it worked well even for people who had tried other quit-smoking medications before or who had made multiple previous attempts to quit.

The potential was highlighted in a lengthy independent report from Hunterbrook in December 2025. That report made a bold claim, calling cytisinicline "likely the best therapy to quit smoking" and noting it could become the first FDA-approved smoking cessation therapy in nearly two decades. That's the kind of potential that gets biotech investors excited, even when the path to market gets a little longer.

For ETF Investors

For investors who prefer to get their exposure through funds, Achieve Life Sciences shows up in at least one ETF with a notable weighting. It's a 6.73% holding in the Simplify Propel Opportunities ETF (SURI).

As for the stock itself, Achieve Life Sciences shares were up a modest 0.13% at $2.824 in Thursday's premarket session, according to market data. The company's story is now one of promising science, a delayed timeline, and the hard financial and regulatory work of bringing a new drug to patients who need it.